Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QCC374
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
QCC374 is a selective prostacyclin (IP) receptor agonist developed by Novartis for the treatment of pulmonary arterial hypertension (PAH). It was administered as an inhaled capsule using a dry powder inhaler. The drug acts by stimulating the prostacyclin receptor, leading to vasodilation and inhibition of platelet aggregation, mechanisms beneficial in PAH. Clinical development included randomized, placebo-controlled trials assessing safety, pharmacokinetics, and efficacy in PAH patients. Despite initial studies showing safety and some efficacy signals, development was discontinued after phase II trials[1][3][5].
- Other names
- QCC 374QCC374QCC-374
02
Targets
PTGIR (Prostanoid IP Receptor)
Beyond the preview
Go deeper on QCC374.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QCC374.